CELSA, Ciro
 Distribuzione geografica
Continente #
NA - Nord America 1.581
EU - Europa 537
AS - Asia 91
AF - Africa 2
SA - Sud America 2
Totale 2.213
Nazione #
US - Stati Uniti d'America 1.579
IT - Italia 285
DE - Germania 116
CN - Cina 58
GB - Regno Unito 38
IE - Irlanda 21
SE - Svezia 16
FI - Finlandia 12
IN - India 12
HK - Hong Kong 11
RO - Romania 11
RU - Federazione Russa 10
BE - Belgio 8
CH - Svizzera 4
FR - Francia 4
NL - Olanda 4
ES - Italia 3
CA - Canada 2
JP - Giappone 2
KR - Corea 2
UA - Ucraina 2
VN - Vietnam 2
AF - Afghanistan, Repubblica islamica di 1
AT - Austria 1
BR - Brasile 1
CL - Cile 1
EG - Egitto 1
GR - Grecia 1
LB - Libano 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
TW - Taiwan 1
Totale 2.213
Città #
Chandler 277
Fairfield 211
Ashburn 154
Woodbridge 83
Ann Arbor 68
Houston 68
Palermo 68
Wilmington 65
Altamura 63
Seattle 63
New York 60
Medford 58
Cambridge 45
Lawrence 36
Princeton 36
Ludwigshafen am Rhein 29
Bremen 27
Des Moines 24
Dublin 21
San Diego 21
Beijing 16
London 16
West Jordan 12
Central 9
Helsinki 9
Rome 9
Brussels 8
Krefeld 8
Venice 8
Boardman 7
Milan 7
Pune 7
Nanjing 6
Dearborn 5
Hanover 5
Kilburn 5
Shenyang 5
Vicopisano 5
Bologna 4
Cagliari 4
Jinan 4
Kumar 4
Messina 4
Aragona 3
Catania 3
Changsha 3
Fasano 3
Jiaxing 3
Lappeenranta 3
Nanchang 3
Saint Petersburg 3
Washington 3
Zhengzhou 3
Aachen 2
Afragola 2
Barcellona Pozzo di Gotto 2
Basel 2
Cologne 2
Erice 2
Gorgonzola 2
Ho Chi Minh City 2
Hong Kong 2
Las Palmas de Gran Canaria 2
Leawood 2
Los Angeles 2
Mehlingen 2
Misterbianco 2
Mistretta 2
Napoli 2
Novellara 2
Oakland 2
Paceco 2
Pavia 2
Perugia 2
Rieti 2
Rimini 2
Seongnam 2
Tokyo 2
Tulsa 2
Tusa 2
Wandsworth 2
Acton 1
Atlanta 1
Aylesbury 1
Bad Durrheim 1
Baiano 1
Bethesda 1
Bobingen 1
Campobasso 1
Chiswick 1
Clearwater 1
Florence 1
Freiburg im Breisgau 1
Fremont 1
Haikou 1
Hangzhou 1
Hebei 1
Islington 1
Isola delle Femmine 1
Kabul 1
Totale 1.749
Nome #
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? 163
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 129
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 126
The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives 109
Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis 109
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use 107
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives 106
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 106
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis 87
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma 82
Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE) 63
Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization? 62
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? 61
Diagnostic performance of endoscopic ultrasound through-the-needle microforceps biopsy of pancreatic cystic lesions: Systematic review with meta-analysis 55
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals 51
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison 50
Systemic therapies for hepatocellular carcinoma: The present and the future 45
Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? 44
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis 42
Biochemical biomarkers of NAFLD/NASH 42
Impact of biliary stents on the diagnostic accuracy of EUS-guided fine-needle biopsy of solid pancreatic head lesions: A multicenter study 42
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials 41
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study 39
Biliary complications after liver transplantation: current perspectives and future strategies 39
Consequences of Extended Spectrum Beta-Lactamase–Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients 39
Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence 38
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices 37
Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials 37
Efficacy of lumen-apposing metal stents or self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: A systematic review and meta-analysis 36
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 35
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 33
Identification of clinical phenotypes and related survival in patients with large hccs 31
Through-the-needle biopsy of pancreatic cystic lesions: stronger evidences of higher diagnostic yield compared with cytology 30
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 29
Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC 28
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis 27
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 26
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD 25
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints 25
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma 24
Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors 24
Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients 24
Reply 22
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model 20
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment 19
Reply 18
Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data 17
Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals 15
Risk profiling of hepatocellular carcinoma occurrence after eradication of hepatitis C virus with direct-acting antiviral agents 14
The relevance of noninvasive tools to assess fibrosis in non-alcoholic fatty liver disease 14
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 14
Reply 14
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation 13
Expert opinion vs. meta-analysis: To be or not to be? 11
Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma 11
Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and individual data 10
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 10
Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study 10
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 8
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 8
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon 6
The price and value of therapeutic synergy in liver cancer 5
null 3
Totale 2.610
Categoria #
all - tutte 16.805
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.805


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201929 0 0 0 0 0 0 0 0 0 0 14 15
2019/2020284 16 2 3 23 16 45 24 19 52 34 40 10
2020/2021354 15 18 30 14 34 16 50 29 51 23 39 35
2021/2022534 50 36 16 17 5 14 10 158 70 32 32 94
2022/2023934 60 165 8 112 82 103 96 73 160 12 36 27
2023/2024462 24 56 39 44 20 154 61 18 17 29 0 0
Totale 2.610